- Home
- GMAB vs ZBRA Comparison
GMAB vs ZBRA Comparison
Compare GMAB & ZBRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- ZBRA
- Stock Information
- Founded
- GMAB 1999
- ZBRA 1969
- Country
- GMAB Denmark
- ZBRA United States
- Employees
- GMAB N/A
- ZBRA N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- ZBRA Industrial Machinery/Components
- Sector
- GMAB Health Care
- ZBRA Industrials
- Exchange
- GMAB Nasdaq
- ZBRA Nasdaq
- Market Cap
- GMAB 15.4B
- ZBRA 16.2B
- IPO Year
- GMAB N/A
- ZBRA 1991
- Fundamental
- Price
- GMAB $28.61
- ZBRA $316.01
- Analyst Decision
- GMAB Buy
- ZBRA Buy
- Analyst Count
- GMAB 6
- ZBRA 8
- Target Price
- GMAB $37.60
- ZBRA $351.13
- AVG Volume (30 Days)
- GMAB 1.4M
- ZBRA 472.3K
- Earning Date
- GMAB 11-05-2025
- ZBRA 10-28-2025
- Dividend Yield
- GMAB N/A
- ZBRA N/A
- EPS Growth
- GMAB 77.72
- ZBRA 138.37
- EPS
- GMAB 21.62
- ZBRA 10.59
- Revenue
- GMAB $3,646,881,232.00
- ZBRA $5,190,000,000.00
- Revenue This Year
- GMAB $22.68
- ZBRA $8.47
- Revenue Next Year
- GMAB $15.85
- ZBRA $7.33
- P/E Ratio
- GMAB $1.32
- ZBRA $29.86
- Revenue Growth
- GMAB 32.97
- ZBRA 19.12
- 52 Week Low
- GMAB $17.24
- ZBRA $205.73
- 52 Week High
- GMAB $28.74
- ZBRA $427.76
- Technical
- Relative Strength Index (RSI)
- GMAB 81.36
- ZBRA 50.09
- Support Level
- GMAB $27.58
- ZBRA $303.55
- Resistance Level
- GMAB $27.61
- ZBRA $318.20
- Average True Range (ATR)
- GMAB 0.37
- ZBRA 7.03
- MACD
- GMAB 0.26
- ZBRA -0.25
- Stochastic Oscillator
- GMAB 97.02
- ZBRA 58.69
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About ZBRA Zebra Technologies Corporation
Zebra Technologies is a leading provider of automatic identification and data capture technology to enterprises. Its solutions include barcode printers and scanners, mobile computers, and workflow optimization software. The firm primarily serves the retail, transportation logistics, manufacturing, and healthcare markets, designing custom solutions to improve efficiency at its customers.